Literature DB >> 21940662

Lymphatic function is regulated by a coordinated expression of lymphangiogenic and anti-lymphangiogenic cytokines.

Jamie C Zampell1, Tomer Avraham, Nicole Yoder, Nicholas Fort, Alan Yan, Evan S Weitman, Babak J Mehrara.   

Abstract

Lymphangiogenic cytokines such as vascular endothelial growth factor-C (VEGF-C) are critically required for lymphatic regeneration; however, in some circumstances, lymphatic function is impaired despite normal or elevated levels of these cytokines. The recent identification of anti-lymphangiogenic molecules such as interferon-γ (IFN-γ), transforming growth factor-β1, and endostatin has led us to hypothesize that impaired lymphatic function may represent a dysregulated balance in the expression of pro/anti-lymphangiogenic stimuli. We observed that nude mice have significantly improved lymphatic function compared with wild-type mice in a tail model of lymphedema. We show that gradients of lymphatic fluid stasis regulate the expression of lymphangiogenic cytokines (VEGF-A, VEGF-C, and hepatocyte growth factor) and that paradoxically the expression of these molecules is increased in wild-type mice. More importantly, we show that as a consequence of T-cell-mediated inflammation, these same gradients also regulate expression patterns of anti-lymphangiogenic molecules corresponding temporally and spatially with impaired lymphatic function in wild-type mice. We show that neutralization of IFN-γ significantly increases inflammatory lymph node lymphangiogenesis independently of changes in VEGF-A or VEGF-C expression, suggesting that alterations in the balance of pro- and anti-lymphangiogenic cytokine expression can regulate lymphatic vessel formation. In conclusion, we show that gradients of lymphatic fluid stasis regulate not only the expression of pro-lymphangiogenic cytokines but also potent suppressors of lymphangiogenesis as a consequence of T-cell inflammation and that modulation of the balance between these stimuli can regulate lymphatic function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940662      PMCID: PMC3328842          DOI: 10.1152/ajpcell.00306.2011

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  39 in total

Review 1.  Incidence of breast carcinoma-related lymphedema.

Authors:  J A Petrek; M C Heelan
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

2.  Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells.

Authors:  Shunsuke Fukumoto; Masayo Morifuji; Yoshinori Katakura; Masamichi Ohishi; Seiji Nakamura
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis.

Authors:  J A Petrek; R T Senie; M Peters; P P Rosen
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

4.  Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin.

Authors:  Jeremy Goldman; Thomas X Le; Mihaela Skobe; Melody A Swartz
Journal:  Circ Res       Date:  2005-05-12       Impact factor: 17.367

5.  Wound healing in nude mice: a study on the regulatory role of lymphocytes in fibroplasia.

Authors:  A Barbul; T Shawe; S M Rotter; J E Efron; H L Wasserkrug; S B Badawy
Journal:  Surgery       Date:  1989-06       Impact factor: 3.982

6.  VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.

Authors:  Young-Sup Yoon; Toshinori Murayama; Edwin Gravereaux; Tengiz Tkebuchava; Marcy Silver; Cynthia Curry; Andrea Wecker; Rudolf Kirchmair; Chun Song Hu; Marianne Kearney; Alan Ashare; David G Jackson; Hajime Kubo; Jeffrey M Isner; Douglas W Losordo
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

7.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Therapeutic lymphangiogenesis with human recombinant VEGF-C.

Authors:  Andrzej Szuba; Mihaela Skobe; Marika J Karkkainen; William S Shin; David P Beynet; Ned B Rockson; Noma Dakhil; Stan Spilman; Michael L Goris; H William Strauss; Thomas Quertermous; Kari Alitalo; Stanley G Rockson
Journal:  FASEB J       Date:  2002-10-18       Impact factor: 5.191

9.  An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.

Authors:  M L Alegre; J Y Tso; H A Sattar; J Smith; F Desalle; M Cole; J A Bluestone
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

10.  Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy.

Authors:  Amy Baker; Harold Kim; John L Semple; Dan Dumont; Molly Shoichet; Dalia Tobbia; Miles Johnston
Journal:  Breast Cancer Res       Date:  2010-09-08       Impact factor: 6.466

View more
  39 in total

1.  Obesity increases inflammation and impairs lymphatic function in a mouse model of lymphedema.

Authors:  Ira L Savetsky; Jeremy S Torrisi; Daniel A Cuzzone; Swapna Ghanta; Nicholas J Albano; Jason C Gardenier; Walter J Joseph; Babak J Mehrara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

Review 2.  Immune cell trafficking, lymphatics and hypertension.

Authors:  Dakshnapriya Balasubbramanian; Catalina A Lopez Gelston; Joseph M Rutkowski; Brett M Mitchell
Journal:  Br J Pharmacol       Date:  2018-06-25       Impact factor: 8.739

Review 3.  Inflammation-associated lymphangiogenesis: a double-edged sword?

Authors:  Honsoul Kim; Raghu P Kataru; Gou Young Koh
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

4.  Inflammation-induced lymphatic architecture and bone turnover changes are ameliorated by irisin treatment in chronic inflammatory bowel disease.

Authors:  S Anand Narayanan; Corinne E Metzger; Susan A Bloomfield; David C Zawieja
Journal:  FASEB J       Date:  2018-03-29       Impact factor: 5.191

Review 5.  Lymphatic Vessel Network Structure and Physiology.

Authors:  Jerome W Breslin; Ying Yang; Joshua P Scallan; Richard S Sweat; Shaquria P Adderley; Walter L Murfee
Journal:  Compr Physiol       Date:  2018-12-13       Impact factor: 9.090

6.  Small Numbers of CD4+ T Cells Can Induce Development of Lymphedema.

Authors:  Catherine L Ly; Daniel A Cuzzone; Raghu P Kataru; Babak J Mehrara
Journal:  Plast Reconstr Surg       Date:  2019-03       Impact factor: 4.730

Review 7.  Tissue engineering and regeneration of lymphatic structures.

Authors:  Evan Weitman; Daniel Cuzzone; Babak J Mehrara
Journal:  Future Oncol       Date:  2013-09       Impact factor: 3.404

Review 8.  Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents.

Authors:  Ravi S J Singh; Judy E Kim
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

Review 9.  New and Emerging Treatments for Lymphedema.

Authors:  Mark V Schaverien; Melissa B Aldrich
Journal:  Semin Plast Surg       Date:  2018-04-09       Impact factor: 2.314

10.  Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema.

Authors:  Stanley G Rockson; Wen Tian; Xinguo Jiang; Tatiana Kuznetsova; Francois Haddad; Jamie Zampell; Babak Mehrara; Joshua P Sampson; Leslie Roche; Jinah Kim; Mark R Nicolls
Journal:  JCI Insight       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.